Postępy Dermatologii i Alergologii

Full text

3/2026 vol. 43
Original paper

TRAF3IP2 (rs13190932) polymorphism in psoriasis and psoriatic arthritis: susceptibility, systemic inflammation and response to methotrexate

Eisa M. Hegazy 1
,
Moustafa A. El Taieb 2
,
Mohammed H. Hassan 3
,
Mahmoud Ahmed Ali 2
,
Shimaa S. Ahmed 4
,
Eslam A. Sadek 5
,
Ebtehal A. Kotop 1
,
Fawzia Mohamed Abd Elzaher 1
,
Soheir Abdel-Hamid 1

  1. Dermatology, Venereology and Andrology Department, Faculty of Medicine, Qena University, Qena, Egypt

  2. Dermatology, Venereology, and Andrology Department, Faculty of Medicine, Aswan University, Aswan, Egypt

  3. Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Qena University, Qena, Egypt

  4. Rheumatology and Rehabilitation Department, Faculty of Medicine, Luxor University, Luxor, Egypt

  5. Department of Public Health and Community Medicine, Faculty of Medicine, Qena University, Qena, Egypt

Adv Dermatol Allergol 2026; XLIII (3): 268–279

DOI: https://doi.org/10.5114/ada.2026.162737
Data publikacji online: 2026/07/19
Article file
PDIA TRAF3IP2.pdf
  1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
  2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021; 397: 1301-15.
  3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
  4. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of cardiovascular disease in psoriasis. JAMA 2011; 306: 1353-60.
  5. Boehncke WH, Boehncke S. Systemic inflammation and cardiovascular comorbidity in psoriasis. Curr Opin Rheumatol 2012; 24: 114-8.
  6. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome. JAMA Dermatol 2013; 149: 1173-80.
  7. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases. J Am Acad Dermatol 2017; 76: 377-90.
  8. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957-70.
  9. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64(Suppl 2): ii14-7.
  10. Chandran V, Gladman DD. Pathogenesis of psoriatic arthritis. Nat Rev Rheumatol 2013; 9: 304-12.
  11. Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis of psoriatic disease. J Invest Dermatol 2015; 135: 1979-88.
  12. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis treatment recommendations. Lancet 2016; 388: 983-994.
  13. Lowes MA, Suarez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32: 227-55.
  14. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Lancet 2018; 391: 110-20.
  15. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation in psoriasis. J Allergy Clin Immunol 2012; 130: 145-54.
  16. Elder JT, Bruce AT, Gudjonsson JE, et al. Molecular dissection of psoriasis: Integrating genetics and biology. J Invest Dermatol 2010; 130: 1213-26.
  17. Tsoi LC, Spain SL, Knight J, et al. Identification of psoriasis susceptibility loci highlights the role of innate immunity. Nat Commun 2017; 8: 15382.
  18. Huffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriasis and psoriatic arthritis. Nat Genet 2010; 42: 996-9.
  19. Giardina E, Sinibaldi C, Chini L, et al. TRAF3IP2 polymorphisms and susceptibility to psoriasis. PLoS One 2011; 6: e16641.
  20. Bowes J, Ashcroft J, Dand N, et al. Cross-phenotype genetic analysis of psoriasis and psoriatic arthritis. Ann Rheum Dis 2015; 74: 1173-81.
  21. Qian Y, Liu C, Hartupee J, et al. The adaptor Act1 is required for IL-17-dependent signaling. Nat Immunol 2007; 8: 247-56.
  22. Herjan T, Hong L, Bubenik J, et al. IL-17 receptor-associated adaptor Act1 stabilizes inflammatory mRNAs. Nat Immunol 2018; 19: 354-65.
  23. Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol 2013; 38: 573-88.
  24. Warren RB, Mrowietz U, von Kiedrowski R, et al. An updated review of methotrexate in psoriasis. Br J Dermatol 2020; 182: 840-53.
  25. Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the Disease Activity Index for PSoriatic Arthritis (DAPSA): a brief review. Clin Exp Rheumatol 2015; 33 (Suppl 93): S48-50.
  26. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatology 1978; 157: 238-44.
  27. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-91.
  28. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20: 1475.
  29. Campalani E, Barker JNWN. Genetics of psoriasis and pharmacogenetics of antipsoriatic drugs. Br J Dermatol 2005; 152: 1109-23.
  30. Smolen JS, Schoels M, Aletaha D, et al. Treating psoriatic arthritis to target. Ann Rheum Dis 2019; 78: 1293-301.
  31. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for psoriasis. J Am Acad Dermatol 2019; 80: 1029-72.
  32. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis. BMJ 2020; 369: m1590.
  33. Puig L. Genetics of psoriasis and psoriatic arthritis: implications for therapy. Expert Rev Clin Immunol 2017; 13: 755-67.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications